Skip to Main Content
SickKids

Hearing Loss: Aminoglycoside-Induced Mitochondrial Deafness

Alternate test name

Streptomycin-Induced deafness; Streptomycin Ototoxicity; MT-RNR1-Related Hearing Loss and Deafness

Gene name / Alternate gene name
  • MTRNR1
  • MTTS1
12s rRNA; tRNA-SER
Protein
Mitochondrially encoded 12S RNA; Mitochondrial transfer RNA, serine 1
Lab area
Genome Diagnostics - Molecular Genetics
Method and equipment
Sequencing
Expected turn-around time
STAT: 4 weeks Routine: 6 weeks
Specimen type

Blood; gDNA. 

For details about specimen requirements, please refer to: Specimen Type & Requirements (PDF).

Specimen requirements

5-10 mL EDTA or ACD 0.5 mL EDTA (neonate); minimum 10 ug in 100 uL low TE (pH8.0)

Storage and transportation

Room Temperature

Special requirements

Special Instructions for Genome Diagnostics Samples

If sample shipment >48 hours, ship on ice.

Background and clinical significance

Non-syndromic mitochondrial hearing loss is characterized by moderate to profound hearing loss, and a maternally inherited mutation in either the MTRNR1 or MTTS1 gene. Individuals with an MTRNR1 mutation may have a predisposition to aminoglycoside ototoxicity causing deafness and/or late onset sensorineural hearing loss. In these individuals, hearing loss associated with aminoglycoside ototoxicity is bilateral and severe to profound, and occurs within a few days to weeks after administration of any amount of aminoglycoside antibiotic. Individuals with an MTTS1 mutation generally have an onset of sensorineural hearing loss during childhood. Variability in clinical findings may be due to the presence of variable numbers of mitochondria containing mutations in different tissues of the body (heteroplasmy).

Disease condition

Hearing Loss: Aminoglycoside-Induced Mitochondrial Deafness

Back to Top